1-BOC-4-氯吲哚-2-硼酸 | 475102-11-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-BOC-4-氯吲哚-2-硼酸
• 中文别名: 1-叔丁氧羰基-4-氯吲哚-2-硼酸；1-Boc-4-氯吲哚-2-硼酸
• 英文名称: [4-chloro-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid
• 英文别名: [1-(tert-butoxycarbonyl)-4-chloro-1H-indol-2-yl]boronic acid；4-chloro-N-boc-indole-2-boronic acid；1-(tert-butoxycarbonyl)-4-chloro-1H-indol-2-ylboronic acid；(1-(tert-Butoxycarbonyl)-4-chloro-1H-indol-2-yl)boronic acid
• CAS: 475102-11-5
• 化学式: C₁₃H₁₅BClNO₄
• 分子量: 295.53
• InChiKey: HUWASNXIUPJIJH-UHFFFAOYSA-N

物化性质

• 熔点：
  107-110
• 沸点：
  471.4±55.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.76
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  71.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-BOC-4-chloroindole-2-boronic acid
Product Name:
Synonyms: 1-BOC-4-chloro-2-indoleboronic acid; 1-(tert-Butoxycarbonyl)-4-chloro-1H-indol-2-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-BOC-4-chloroindole-2-boronic acid
Ingredient name:
CAS number: 475102-11-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C13H15BClNO4
Molecular weight: 295.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-bromo-2-chloro-N-cyclohexyl-benzenesulfonamide 、 1-BOC-4-氯吲哚-2-硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride cesium fluoride 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 2.0h， 生成 4-chloro-2-(4-chloro-3-cyclohexylsulfamoyl-phenyl)-indole-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2008/14186

  摘要：

  公开号：
• 作为产物：
  描述：

  4-氯吲哚 在 4-二甲氨基吡啶 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.0h， 生成 1-BOC-4-氯吲哚-2-硼酸
  参考文献：
  名称：

  [EN] 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF
  [FR] DÉRIVÉS DE 1,3,5-TRIAZINE-2-AMINE, PROCÉDÉ DE PRÉPARATION DE CEUX-CI ET UTILISATION DIAGNOSTIQUE ET THÉRAPEUTIQUE DE CES DÉRIVÉS

  摘要：

  本发明涉及与以下式（I）对应的化合物：- R1代表取代苯基；- R2代表：- 取代苯基；- 杂芳基团，所述基团未取代或取代一次或多次；- R3代表羟基烷基基团；- R4代表氢原子或（C1-C4）烷基；- R5代表氢原子，（C3-C6）环烷基或（C1-C4）烷基-O-烷基；- 或者R4和R5，连同它们连接的氮原子，构成从以下中选择的杂环基团：氮杂环丙烷-1-基，吡咯烷-1-基，哌啶-1-基，吗啉-4-基；- R6代表-羟基烷基基团，-酰胺基或-NHSO2烷基基团；- 烷基代表未取代或取代一次或多次的（C1-C4）烷基，其上带有卤原子；以碱或酸盐的形式。制备过程和诊断和治疗用途。

  公开号：

  WO2013087643A1

文献信息

• 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：YANG Zhaoxia

  公开号：US20090176804A1

  公开（公告）日：2009-07-09

  The present invention is directed to 2-phenyl-indole compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, eczema, urticaria diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like.

  本发明涉及2-苯基吲哚化合物、它们的制备、含有这些化合物的制药组合物，以及它们在治疗患有PGD2介导的疾病的患者中的制药用途，包括但不限于过敏性疾病（如过敏性鼻炎、过敏性结膜炎、特应性皮炎、支气管哮喘和食物过敏）、全身性肥大细胞增多症、伴随全身性肥大细胞激活的疾病、过敏性休克、支气管痉挛、支气管炎、湿疹、荨麻疹等伴随瘙痒的疾病（如特应性皮炎和荨麻疹）、因瘙痒引起的继发性疾病（如白内障、视网膜脱离、炎症、感染和睡眠障碍）、炎症、慢性阻塞性肺疾病、缺血再灌注损伤、脑血管意外、慢性类风湿性关节炎、胸膜炎、溃疡性结肠炎等。
• Specific Inhibitor of Placental Alkaline Phosphatase Isolated from a DNA-Encoded Chemical Library Targets Tumor of the Female Reproductive Tract
  作者：Gabriele Bassi、Nicholas Favalli、Christian Pellegrino、Yuichi Onda、Jörg Scheuermann、Samuele Cazzamalli、Markus G. Manz、Dario Neri

  DOI：10.1021/acs.jmedchem.1c01103

  日期：2021.11.11
• A Non-cryogenic Method for the Preparation of 2-(Indolyl) Borates, Silanes, and Silanols
  作者：Enrique Vazquez、Ian W. Davies、Joseph F. Payack

  DOI：10.1021/jo026087j

  日期：2002.10.1

  2-Indolyl borates are prepared via addition of LDA to a mixture of N-Boc-indole and triisopropyl borate at 0-5 degreesC. Following acidic hydrolysis, the boronic acids are isolated by crystallization in good to excellent yield (73-99%). The method is quite general, tolerating a wide range of functional groups, and also provides access to 2-silyl derivatives (80-91%).
• Development of <i>Toxoplasma gondii</i> Calcium-Dependent Protein Kinase 1 (<i>Tg</i>CDPK1) Inhibitors with Potent Anti-<i>Toxoplasma</i> Activity
  作者：Steven M. Johnson、Ryan C. Murphy、Jennifer A. Geiger、Amy E. DeRocher、Zhongsheng Zhang、Kayode K. Ojo、Eric T. Larson、B. Gayani K. Perera、Edward J. Dale、Panqing He、Molly C. Reid、Anna M. W. Fox、Natascha R. Mueller、Ethan A. Merritt、Erkang Fan、Marilyn Parsons、Wesley C. Van Voorhis、Dustin J. Maly

  DOI：10.1021/jm201713h

  日期：2012.3.8

  Toxoplasmosis is a disease of prominent health concern that is caused by the protozoan parasite Toxoplasma gondii. Proliferation of T. gondii is dependent on its ability to invade host cells, which is mediated in part by calcium-dependent protein kinase 1 (CDPK1). We have developed ATP competitive inhibitors of TgCDPK1 that block invasion of parasites into host cells, preventing their proliferation. The presence of a unique glycine gatekeeper residue in TgCDPK1 permits selective inhibition of the parasite enzyme over human kinases. These potent TgCDPK1 inhibitors do not inhibit the growth of human cell lines and represent promising candidates as toxoplasmosis therapeutics.